



NCI Legislative Update

Clinical Trials Advisory Committee July 13, 2011

M.K. Holohan, J.D.
Deputy Director, Office of Government and
Congressional Relations



Discussion Topics

Appropriations Process (?)

Congressional Interests

Legislation Highlights

Appropriations Status

What Has Already Happened?

- ✓ Feb. 14 – PB announced
NIH \$31.0 Billion; NCI \$5.1 Billion
- ✓ May 11 – Senate Appropriations Hearing
7 Senators attended (D-4; R-3)
NIH Director + 4 Institute Directors testified



No House hearing planned

Debt Limit Discussion – July 7



July 10



Appropriations Stalled...

Senate appropriations process on hold pending based on debt discussions

- House cancelled July 18-22 recess to work on debt negotiations



Appropriations Status

What Happens Next?

- Subcommittees write bills and reports
- Subcommittees mark up and vote
 - House-scheduled July 26 (sub) and Aug 2 (full)
 - Senate – no schedule, pending debt limit deal
- Recess August 8 – Sept 5



Input to Senate Appropriators

“...request that you maintain a strong commitment to funding for the NIH

... best hope for treating debilitating diseases like heart disease, cancer...

...urge you to consider the tremendous benefits of sustaining investment in the NIH

...we must continue to invest in areas like biomedical research that have the potential to save money in the future, improve the lives of Americans, and offer an economic return for our Nation.”

Signed by 41 Senators (34 Democrat; 7 Republican)

Slight encouragement...

- The House Appropriations Committee marked up the Commerce-Justice-Science bill last week and continued the National Science Foundation budget at the same level as FY11 (\$6.9 billion)

“to enhance basic research that is critical to innovation and U.S. economic competitiveness.”





Discussion Topics

Appropriations Process

Congressional Interests

Legislation Highlights



Congress is Asking About

- ✓ Clinical Trials Consolidation
 - NCI provided briefing and responded to letters
- ✓ Cancer Center Funding
 - NCI spoke with members and staff and responded to letters
- ✓ Pancreatic Cancer Legislation
 - NCI responded to questions
- ✓ Pediatric Cancer
 - NCI provided briefing and proposed visit



Discussion Topics

Appropriations Process

Congressional Interests

Legislation Highlights



Legislation Highlights

Consistency, Accuracy, Responsibility, Excellence in
Medical Imaging and Radiation Therapy Act

HR 2104 – Rep. Whitfield (R-KY)

Increase safety and accuracy

Require federal minimum qualification standards

Preserving Access to Life-Saving Medications Act

S 296 – Sens. Klobuchar (D-MN) Casey (D-PA)

HR 2245–Reps Rooney (R- FL) DeGette (D-CO)

Requires FDA notification of discontinuance,
interruption likely to result in shortage

Evidence-based criteria to ID vulnerable drugs

GAO study of possible causes of shortages



Legislation Highlights

Disease-specific Bills

Lung Cancer Mortality Reduction Act

HR 1394 – Del. Christensen (D-VI)

S 752 – Sen. Feinstein (D-CA)

Pancreatic Cancer Research and Education Act


HR 733 – Rep. Eshoo (D-CA)

S 362 – Sen. Whitehouse (D-RI)

Prostate Cancer Research, Outreach, Screening,
Testing, Access and Treatment Effectiveness

HR 2159 – Rep. Towns (D-NY)

S 1190 – Sen. Tester (D-MT)



NATIONAL[®]
CANCER
INSTITUTE
